Royalty Pharma plc Other Noncash Income (Expense)
Royalty Pharma plc (RPRX) reported Other Noncash Income (Expense) of -$5.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-05
- Royalty Pharma plc other noncash income (expense) for the quarter ending 2026-06-30 was -$3.42M.
- Royalty Pharma plc other noncash income (expense) for the quarter ending 2026-03-31 was -$1.89M.
- Royalty Pharma plc other noncash income (expense) for the quarter ending 2025-12-31 was -$8.49M.
- Royalty Pharma plc other noncash income (expense) for the quarter ending 2025-09-30 was -$2.16M.
- Royalty Pharma plc other noncash income (expense) for fiscal 2025 was -$13.31M.
- Royalty Pharma plc other noncash income (expense) for fiscal 2024 was -$1.10M.
- Royalty Pharma plc other noncash income (expense) for fiscal 2023 was -$20.91M.
- Royalty Pharma plc other noncash income (expense) for fiscal 2022 was -$11.10M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.31M 10-Q · filed 2026-08-05 | -$13.79M derived: sum of 3 quarters · filed 2026-08-05 | -$15.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.89M 10-Q · filed 2026-05-06 | -$10.38M derived: sum of 2 quarters · filed 2026-05-06 | -$12.54M derived: sum of 3 quarters · filed 2026-05-06 | -$14.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$8.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$10.65M derived: sum of 2 quarters · filed 2026-02-11 | -$12.20M derived: sum of 3 quarters · filed 2026-08-05 | -$13.31M 10-K · filed 2026-02-11 |
| 2025-09-30 | -$2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$3.71M derived: sum of 2 quarters · filed 2026-08-05 | -$4.82M 10-Q · filed 2025-11-05 | -$7.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.66M 10-Q · filed 2026-08-05 | -$5.56M derived: sum of 3 quarters · filed 2026-08-05 | -$6.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.10M 10-Q · filed 2026-05-06 | -$4.01M derived: sum of 2 quarters · filed 2026-05-06 | -$5.21M derived: sum of 3 quarters · filed 2026-05-06 | $838.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$4.11M derived: sum of 2 quarters · filed 2026-02-11 | $1.94M derived: sum of 3 quarters · filed 2026-02-11 | -$1.10M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.85M derived: sum of 2 quarters · filed 2025-11-05 | $1.80M 10-Q · filed 2025-11-05 | -$15.85M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $6.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.00M 10-Q · filed 2025-08-06 | -$14.64M derived: sum of 3 quarters · filed 2026-02-11 | -$16.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$3.05M 10-Q · filed 2025-05-08 | -$20.70M derived: sum of 2 quarters · filed 2026-02-11 | -$22.05M derived: sum of 3 quarters · filed 2026-02-11 | -$20.81M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$17.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$19.01M derived: sum of 2 quarters · filed 2026-02-11 | -$17.77M derived: sum of 3 quarters · filed 2026-02-11 | -$20.91M 10-K · filed 2026-02-11 |
| 2023-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$116.00K derived: sum of 2 quarters · filed 2024-11-06 | -$3.26M 10-Q · filed 2024-11-06 | -$10.92M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.91M 10-Q · filed 2024-08-08 | -$9.56M derived: sum of 3 quarters · filed 2025-02-12 | -$10.35M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$3.15M 10-Q · filed 2024-05-09 | -$10.80M derived: sum of 2 quarters · filed 2025-02-12 | -$11.59M derived: sum of 3 quarters · filed 2025-02-12 | -$12.72M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$8.44M derived: sum of 2 quarters · filed 2025-02-12 | -$9.57M derived: sum of 3 quarters · filed 2025-02-12 | -$11.10M 10-K · filed 2025-02-12 |
| 2022-09-30 | -$786.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$1.92M derived: sum of 2 quarters · filed 2023-11-08 | -$3.44M 10-Q · filed 2023-11-08 | -$4.64M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.66M 10-Q · filed 2023-08-08 | -$3.85M derived: sum of 3 quarters · filed 2024-02-15 | -$5.07M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$1.52M 10-Q · filed 2023-05-09 | -$2.72M derived: sum of 2 quarters · filed 2024-02-15 | -$3.94M derived: sum of 3 quarters · filed 2024-02-15 | -$5.03M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$2.41M derived: sum of 2 quarters · filed 2024-02-15 | -$3.50M derived: sum of 3 quarters · filed 2024-02-15 | -$4.46M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$2.31M derived: sum of 2 quarters · filed 2022-11-08 | -$3.26M 10-Q · filed 2022-11-08 | -$4.72M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | -$1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$2.05M 10-Q · filed 2022-08-04 | -$3.51M derived: sum of 3 quarters · filed 2023-02-15 | -$8.27M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | -$958.00K 10-Q · filed 2022-05-05 | -$2.42M derived: sum of 2 quarters · filed 2023-02-15 | -$7.18M derived: sum of 3 quarters · filed 2023-02-15 | -$7.11M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | -$1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$6.22M derived: sum of 2 quarters · filed 2023-02-15 | -$6.15M derived: sum of 3 quarters · filed 2023-02-15 | -$9.62M 10-K · filed 2023-02-15 |
| 2020-09-30 | -$4.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$4.69M derived: sum of 2 quarters · filed 2021-11-10 | -$8.16M 10-Q · filed 2021-11-10 | -$6.41M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$3.40M 10-Q · filed 2021-08-11 | -$1.65M derived: sum of 3 quarters · filed 2022-02-15 | -$987.00K derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$3.47M 10-Q · filed 2021-05-11 | -$1.72M derived: sum of 2 quarters · filed 2022-02-15 | -$1.06M derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $2.41M derived: sum of 2 quarters · filed 2022-02-15 | $2.12M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $659.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $370.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$289.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $7.77M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |